Agilent Acquisition FAQ’s

BIOVECTRA: Now Part of Agilent

Agilent is pleased to announce that BIOVECTRA, a Canada-based specialized Contract Development and Manufacturing Organization (CDMO), is now part of our company.

By joining together, Agilent and BIOVECTRA will offer our pharmaceutical customers an even broader range of active pharmaceutical ingredient (API) manufacturing capabilities for targeted therapeutics.

The following frequently-asked-questions provide current and future customers of Agilent and BIOVECTRA with general information, new capabilities we can now offer, and how to learn more.

Please continue working with your existing BIOVECTRA representative or team as usual. If you don’t have a regular contact, you can always reach the BIOVECTRA team here.

This acquisition will enable Agilent to provide our customers even more specialized manufacturing capabilities for targeted therapeutics, from sterile fill-finish to a single source for gene-editing technology.

To learn more about our expanded capabilities and how they may benefit your programs in the future, contact our team here.

BIOVECTRA brings valuable services and capabilities to Agilent, including:

Learn more about these offerings at Biovectra.com and contact the BIOVECTRA team here with any questions about them.

Like Agilent, BIOVECTRA can also manufacture large quantities of material to support clinical-to-commercial needs.

By combining BIOVECTRA’s complementary capabilities in biologics with our expertise in gRNA, Agilent will be able to provide customers with a single source for gene-editing technology. To learn more, email us here.

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors